Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2Lymphoid 2

Conditions

Myelodysplastic Syndromes 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Multiple Myeloma 6Leukemia 6Leukemia, Myelomonocytic, Chronic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Blast Crisis 5Lymphohistiocytosis, Hemophagocytic 4Hodgkin Disease 4Hematologic Neoplasms 4Primary Myelofibrosis 3Myeloproliferative Disorders 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Hairy Cell 3Burkitt Lymphoma 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Vomiting 2Testicular Neoplasms 2Sezary Syndrome 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neuroblastoma 2Nausea 2Myelodysplastic-Myeloproliferative Diseases 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

Cyclophosphamide 8fludarabine phosphate 7tagraxofusp 6venetoclax 5fludarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Methotrexate 4Thiotepa 3Dexamethasone 3Cytarabine 3Cyclosporine 3Calcium Dobesilate 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Tacrolimus 2Specimen Handling 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Cyclosporins 2Azacitidine 2relmapirazin 1prednylidene 1lorvotuzumab mertansine 1exifone 1deltacortene 1azathiopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Blastic Plasmacytoid Dendritic Cell Neoplasm × Dexamethasone × Myeloid × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05476770 2024-12-06

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Recruiting
54 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Biphenotypic, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡